9 June 2016 - PHARMAC is today announcing funding of six new treatments across important areas of health, including major advancements in the treatment of hepatitis C.

From 1 July 2016, the following treatments will be fully funded (some with access criteria):

• Harvoni and Viekira Pak for hepatitis C infection
• Nivolumab (Opdivo) for advanced melanoma
• Rituximab for nephrotic syndrome in children

The following treatments will also be fully funded (some with access criteria):

• From 1 August 2016: Oestradiol patches for menopausal women
  From 1 December 2016: Temozolomide for brain tumours and neuroendocrine tumours

For more details, go to: http://www.pharmac.govt.nz/news/media-2016-06-09-funding-announcements/